Poolbeg Pharma – Results for the year ended 31 December 2023
Significant pipeline advancements
Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn
Key senior management hires
30 April 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces its audited results for the year ended 31 December 2023.
